Lidia Fonseca - 27 Feb 2025 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
/s/ Shanice A. Reid, by power of atty, for Lidia Fonseca
Issuer symbol
PFE
Transactions as of
27 Feb 2025
Net transactions value
-$1,816,580
Form type
4
Filing time
03 Mar 2025, 17:36:36 UTC
Previous filing
16 Sep 2024
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $2,274,014 +72,629 +187% $31.31 111,534 27 Feb 2025 Direct F1
transaction PFE Common Stock Tax liability $43,926 -1,683 -1.5% $26.10 109,851 27 Feb 2025 Direct F2
transaction PFE Common Stock Tax liability $1,772,653 -68,022 -62% $26.06 41,829 27 Feb 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $2,274,014 -72,629 -100% $31.31 0 27 Feb 2025 Common Stock 72,629 $31.31 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

Remarks:

lfxpoa24.htm